The protocol of choice for potential high-responder patients prone to develop OHSS should be the GnRH antagonist protocol, as it has been shown to decrease the incidence of OHSS significantly [7,8]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.